Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-jr42d Total loading time: 0 Render date: 2024-04-25T00:12:56.660Z Has data issue: false hasContentIssue false

Chapter 27 - Movement disorders emergencies

from Section V - Systemic complications of movement disorders

Published online by Cambridge University Press:  05 April 2014

By
Ritesh A. Ramdhani  and
Steven J. Frucht
Edited by
Werner Poewe  and
Joseph Jankovic
Ritesh A. Ramdhani
Affiliation:
Movement Disorders Division, Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
Steven J. Frucht
Affiliation:
Movement Disorders Division, Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
Werner Poewe
Affiliation:
Medical University Innsbruck
Joseph Jankovic
Affiliation:
Baylor College of Medicine, Texas
Get access

Summary

Introduction

A movement disorder emergency is defined as any movement disorder that evolves or clinically worsens over hours to days. It can occur with hypokinetic as well as hyperkinetic conditions. The systemic and neurological sequelae can originate from the inherent disease process, excessive movements, or a combination of both. Failure to recognize and efficiently manage these patients carries a significant risk of morbidity and mortality.

We review the six major categories of movement disorder emergencies: parkinsonism, dystonia, chorea, myoclonus, tics, and emergencies associated with deep brain stimulation.

Acute parkinsonism

Acute parkinsonism, or non-neurodegenerative parkinsonism, develops suddenly over hours to days. Unlike idiopathic Parkinson’s disease (PD), symptoms are usually symmetric, with prominent bradykinesia and rigidity. Dopamine-blocking medications are the most common precipitants. Consideration of rarer etiologies such as toxins and chemotherapy, structural lesions, and rapid dystonia-parkinsonism, viral encephalitis, and neuroleptic malignant syndrome is predicated in the clinical context (Table 27.1).

Drug-induced parkinsonism

Drug-induced parkinsonism (DIP) is commonly caused by medications that affect dopamine efficacy either by blocking its receptors or depleting its stores (i.e. neuroleptics, antiemetics). As many as 60 percent of patients develop symptoms within one month of initiating these medications, and 90 percent by the third month (Quinn 1995). Its incidence increases with age and it tends to have a bimodal distribution, with an initial peak in adolescence and a second peak after the sixth decade (Susatia and Fernandez 2009). Women are twice as likely as men to be affected, and the risk of developing it correlates with the potency of the drug (Ayd 1961).

Type
Chapter
Information
Movement Disorders in Neurologic and Systemic Disease , pp. 419 - 441
Publisher: Cambridge University Press
Print publication year: 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adler, C. H., Stern, M. B., and Brooks, M. L. (1989). “Parkinsonism secondary to bilateral striatal fungal abscesses,” Mov. Disord. 4(4): 333–7.CrossRefGoogle ScholarPubMed
Ahmed, S., Chengappa, K. N., Naidu, V. R., Baker, R. W., Parepally, H., and Schooler, N. R. (1998). “Clozapine withdrawal-emergent dystonias and dyskinesias: a case series,” J. Clin. Psychiatry 59: 472–7.CrossRefGoogle ScholarPubMed
Anderson, M. (2000). “Neurology of Whipple’s disease,” J. Neurol. Neurosurg. Psychiatry 68(1): 2–5.CrossRefGoogle ScholarPubMed
Arpesella, R., Dallocchio, C., Arbasino, C., Imberti, R., Martinotti, R., and Frucht, S. J. (2009). “A patient with intractable posthypoxic myoclonus (Lance-Adams syndrome) treated with sodium oxybate,” Anaesth. Intens. Care 37(2): 314–18.Google ScholarPubMed
Avorn, J., Gurwitz, J. H., Bohn, R. L., Mogun, H., Monane, M., and Walker, A. (1995). “Increased incidence of levodopa therapy following metoclopramide use,” JAMA 274(22): 1780–2.CrossRefGoogle ScholarPubMed
Ayd, F. J. (1961). “A survey of drug-induced extrapyramidal reactions,” JAMA 175: 1054–60.CrossRefGoogle ScholarPubMed
Baizabal-Carvallo, J. F., Simpson, R., and Jankovic, J. (2011). “Diagnosis and treatment of complications related to deep brain stimulation hardware,” Mov. Disord. 26(8): 1398–406.CrossRefGoogle ScholarPubMed
Baizabal-Carvallo, J. F., Mostile, G., Almaguer, M., Davidson, A., Simpson, R., and Jankovic, J. (2012). “Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations,” Stereotact. Funct. Neurosurg. 90(5): 300–6.CrossRefGoogle ScholarPubMed
Berry, D. S. and Moriarty, R. A. (1999). “Atlantoaxial subluxation related to pharyngitis: Grisel’s syndrome,” Clin. Pediatr. 38(11): 673–5.CrossRefGoogle ScholarPubMed
Bhatt, M. H., Elias, M. A., and Mankodi, A. K. (1999). “Acute and reversible parkinsonism due to organophosphate pesticide intoxication: five cases,” Neurology 52: 1467–71.CrossRefGoogle ScholarPubMed
Bibbiani, F., Costantini, L. C., Patel, R., and Chase, T. N. (2005). “Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates,” Exp. Neurol. 192(1): 73–8.CrossRefGoogle ScholarPubMed
Boranic, M. and Raci, F. (1979). “A Parkinson-like syndrome as side effect of chemotherapy with vincristine and adriamycin in a child with acute leukaemia,” Biomedicine 31(5): 124–5.Google Scholar
Bower, J. H. and Muenter, M. D. (1995). “Temporary worsening of parkinsonism in a patient with Parkinson’s disease after treatment with paclitaxel for a metastatic grade IV adenocarcinoma,” Mov. Disord. 10(5): 681–2.CrossRefGoogle Scholar
Brashear, A., Dobyns, W. B., de Carvalho Aguiar, P., Borg, M., Frijns, C. J., Gollamudi, S., et al. (2007). “The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene,” Brain 130(Pt. 3): 828–35.CrossRefGoogle ScholarPubMed
Bredenkamp, J. K. and Maceri, D. R. (1990). “Inflammatory torticollis in children,” Arch. Otolaryngol. Head Neck Surg. 116: 310–13.CrossRefGoogle ScholarPubMed
Brouns, R. and De Deyn, P. P. (2004). “Neurological complications in renal failure: a review,” Clin. Neurol. Neurosurg. 107(1): 1–16.CrossRefGoogle ScholarPubMed
Cantini, R., Ferrito, G., Lutzemberger, L., and Marcacci, G. (1988). “Parkinsonian syndrome in the course of aqueductal stenosis hydrocephalus,” Ital. J. Neurol. Sci. 9: 603–6.CrossRefGoogle ScholarPubMed
Cheung, M. Y., Shahed, J., and Jankovic, J. (2007). “Malignant Tourette syndrome,” Mov. Disord. 22(12): 1743–50.CrossRefGoogle ScholarPubMed
Choi, I. S. and Cheon, H. Y. (1999). “Delayed movement disorders after carbon monoxide poisoning,” Eur. Neurol. 42(3): 141–4.CrossRefGoogle ScholarPubMed
Curran, T. and Lang, A. E. (1994). “Parkinsonian syndromes associated with hydrocephalus: case reports, a review of the literature, and pathophysiological hypotheses,” Mov. Disord. 9: 508–20.CrossRefGoogle ScholarPubMed
Dalmau, J. and Rosenfeld, M. R. (2011). “Paraneoplastic syndromes causing movement disorders” in Vinken, P. J. and Bruyn, G. W. (eds.,) Handbook of Clinical Neurology (Amsterdam: Elsevier), pp. 315–21.Google Scholar
Dalmau, J., Tuzun, E., Wu, H. Y., Masjuan, J., Rossi, J. E., Voloschin, A., et al. (2007). “Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma,” Ann. Neurol. 61(1): 25–36.CrossRefGoogle ScholarPubMed
Dalvi, A., Fahn, S., and Ford, B. (1998). “Intrathecal baclofen in the treatment of dystonic storm,” Mov. Disord. 13(3): 611–12.CrossRefGoogle ScholarPubMed
de Carvalho Aguiar, P., Sweadner, K. J., Penniston, J. T., Zaremba, J., Liu, L., Caton, M., et al. (2004). “Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism,” Neuron. 43(2): 169–75.CrossRefGoogle ScholarPubMed
Dewey, R. B. and Jankovic, J. (1989). “Hemiballism-hemichorea: clinical and pharmacologic findings in 21 patients,” Arch. Neurol. 46(8): 862–7.CrossRefGoogle ScholarPubMed
Duvoisin, R. C., Yahr, M. D., Schweitzer, M. D., and Merritt, H. H. (1963). “Parkinsonism before and since the epidemic of encephalitis lethargica,” Arch. Neurol. 9: 232–6.CrossRefGoogle ScholarPubMed
Espay, A. J. (2008). “Reversible parkinsonism and ataxia associated with high-dose octreotide,” Neurology 70(24): 2345–6.CrossRefGoogle ScholarPubMed
Factor, S. A., Podskalny, G. D., and Barron, K. D. (1994). “Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: a clinico-pathological case report,” J. Neurol. Sci. 127(1): 114–20.CrossRefGoogle ScholarPubMed
Féve, A., Angelard, B., Fénelon, G., Logak, M., Guillard, A., and Lacau Saint-Guily, J. (1993). “Postneuroleptic laryngeal dyskinesias: a cause of upper airway obstructive syndrome improved by local injections of botulinum toxin,” Mov. Disord. 8(2): 217–19.CrossRefGoogle ScholarPubMed
Fève, A., Angelard, B., and Guily, J. (1995). “Laryngeal tardive dyskinesia,” J. Neurol. 242: 455–9.
Fleming, D. R. and Mangino, P. B. (1997). “Parkinsonian syndrome in a dialysis-supported patient receiving high-dose chemotherapy for multiple myeloma,” Southern Med. J. 90(3): 364–5.CrossRefGoogle Scholar
Friedman, J. H., Feinberg, S. S., and Feldman, R. G. (1985). “A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal,” JAMA 254(19): 2792–5.CrossRefGoogle Scholar
Frucht, S. (2005). “Movement disorder emergencies,” Curr. Neurol. Neurosci. Rep. 5(4): 284–93.CrossRefGoogle ScholarPubMed
Frucht, S. J. (2004). “Movement disorder emergencies in the perioperative period,” Neurol. Clin. 22(2): 379–87.CrossRefGoogle ScholarPubMed
Furukawa, Y. and Kish, S. J. (1999). “Dopa-responsive dystonia: recent advances and remaining issues to be addressed,” Mov. Disord. 14(5): 709–15.3.0.CO;2-T>CrossRefGoogle ScholarPubMed
Gan, E. C., Lau, D. P., and Cheah, K. L. (2010). “Stridor in Parkinson’s disease: a case of ‘dry drowning’?” J. Laryngol. Otol. 124(6): 668–73.CrossRefGoogle ScholarPubMed
Geyer, H. L. and Bressman, S. B. (2011). “Rapid-onset dystonia-parkinsonism” in Vinken, P. J. and Bruyn, G. W. (eds.,) Handbook of Clinical Neurology (Amsterdam: Elsevier), pp. 559–62.Google Scholar
Goetz, C. G. and Klawans, H. L. (1980). “Gilles de la Tourette syndrome and compressive neuropathies,” Ann. Neurol. 8(4): 453.CrossRefGoogle ScholarPubMed
Gorman, M. and Barkley, G. L. (1995). “Oculogyric crisis induced by carbamazepine,” Epilepsia 36(11): 1158–60.CrossRefGoogle ScholarPubMed
Granner, M. A. and Wooten, G. F. (1991). “Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome,” Semin. Neurol. 11: 228–35.CrossRefGoogle ScholarPubMed
Gwiazda, R. H., Lee, D., Sheridan, J., and Smith, D. R. (2002). “Low cumulative manganese exposure affects striatal GABA but not dopamine,” Neurotoxicology 23(1): 69–76.CrossRefGoogle Scholar
Harbord, M. G. and Kobayashi, J. S. (1991). “Fever producing ballismus in patients with choreoathetosis,” J. Child Neurol. 6: 49–52.CrossRefGoogle ScholarPubMed
Hariz, M. I. and Johansson, F. (2001). “Hardware failure in parkinsonian patients with chronic subthalamic nucleus stimulation is a medical emergency,” Mov. Disord. 16(1): 166–8.3.0.CO;2-S>CrossRefGoogle ScholarPubMed
Heimburger, R. F. (1988). “Positional oculogyric crises. Case report,” J. Neurosurg. 69(6): 951–3.CrossRefGoogle ScholarPubMed
Horiguchi, J. and Inami, Y. (1989). “Effect of clonazepam on neuroleptic-induced oculogyric crisis,” Acta Psychiat. Scand. 80(5): 521–3.CrossRefGoogle ScholarPubMed
Howard, R. S. and Lees, A. J. (1987). “Encephalitis lethargica. A report of four recent cases,” Brain 110(Pt. 1): 19–33.CrossRefGoogle ScholarPubMed
Iranzo, A., Santamaria, J., Tolosa, E., Vilaseca, I., Valldeoriola, F., Martí, M. J., et al. (2004). “Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy,” Neurology 63(5): 930–2.CrossRefGoogle ScholarPubMed
Isozaki, E., Shimizu, T., Takamoto, K., Horiguchi, S., Hayashida, T., Oda, M., et al. (1995). “Vocal cord abductor paralysis (VCAP) in Parkinson’s disease: difference from VCAP in multiple system atrophy,” J. Neurol. Sci. 130(2): 197–202.CrossRefGoogle ScholarPubMed
Jagoda, A., Riggio, S., and Burguieres, T. (1988). “Cephalic tetanus: a case report and review of the literature,” Am. J. Emerg. Med. 6(2): 128–30.CrossRefGoogle ScholarPubMed
Jamora, D., Lim, S. H., Pan, A., Tan, L., and Tan, E. K. (2007). “Valproate-induced parkinsonism in epilepsy patients,” Mov. Disord. 22:130–3.CrossRefGoogle ScholarPubMed
Jankovic, J. and Clarence-Smith, K. (2011). “Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders,” Expert Rev. Neurother. 11(11): 1509–23.CrossRefGoogle ScholarPubMed
Jankovic, J. and Penn, A. S. (1982). “Severe dystonia and myoglobinuria,” Neurology 32(10): 1195–7.CrossRefGoogle ScholarPubMed
Kajitani, M., Yagura, H., Kawahara, M., Hirano, M., Ueno, S., Fujimoto, K., et al. (2007). “Treatable fluctuating parkinsonism and dementia in a patient with a dural arteriovenous fistula,” Mov. Disord. 22(3): 437–9.CrossRefGoogle Scholar
Kenney, C., Simpson, R., Hunter, C., Ondo, W., Almaguer, M., Davidson, A., et al. (2007). “Short-term and long-term safety of deep brain stimulation in the treatment of movement disorders,” J. Neurosurg. 106(4): 621–5.CrossRefGoogle ScholarPubMed
Kirkham, F. J., Haywood, P., Kashyape, P., Borbone, J., Lording, A., Pryde, K., et al. (2011). “Movement disorder emergencies in childhood,” Eur. J. Paediatr. Neurol. 15(5): 390–404.CrossRefGoogle ScholarPubMed
Klausner, J. M., Caspi, J., Lelcuk, S., Khazam, A., Marin, G., Hechtman, H. B., et al. (1988). “Delayed muscular rigidity and respiratory depression following fentanyl anesthesia,” Arch. Surg. 123(1): 66–7.CrossRefGoogle ScholarPubMed
Koek, R. and Pi, E. (1989). “Acute laryngeal dystonic reactions to neuroleptics,” Psychosomatics 30: 359–64.CrossRefGoogle ScholarPubMed
Kovacs, N., Balas, I., Janszky, J., Simon, M., Fekete, S., and Komoly, S. (2011). “Status dystonicus in tardive dystonia successfully treated by bilateral deep brain stimulation,” Clin. Neurol. Neurosurg. 113(9): 808–9.CrossRefGoogle ScholarPubMed
Krauss, J. K., Akeyson, E. W., Giam, P., and Jankovic, J. (1996). “Propofol-induced dyskinesias in Parkinson’s disease,” Anesth. Analg. 83(2): 420–2.Google ScholarPubMed
Krauss, J. K and Jankovic, J. (1996). “Severe motor tics causing cervical myelopathy in Tourette’s syndrome,” Mov. Disord. 11(5): 563–6.CrossRefGoogle ScholarPubMed
Krishnamoorthy, K. S., Zalneraitis, E. L., Young, R. S. K., and Bernad, P. G. (1983). “Phenytoin-induced choreoathetosis in infancy: case reports and a review,” Pediatrics 72(6): 831–4.Google ScholarPubMed
Lee, P. H., Lee, J. S., Shin, D. H., Kim, B. M., and Huh, K. (2005). “Parkinsonism as an initial manifestation of dural arteriovenous fistula,” Eur. J. Neurol. 12(5): 403–6.CrossRefGoogle ScholarPubMed
Lew, M. F., Shindo, M., Moskowitz, C. B., Wilhelmsen, K. C., Fahn, S., and Waters, C. H. (1994). “Adductor laryngeal breathing dystonia in a patient with lubag (X-linked dystonia-parkinsonism syndrome),” Mov. Disord. 9: 318–20.CrossRefGoogle Scholar
Low, H. L., Sayer, F. T., and Honey, C. R. (2008). “Pathological crying caused by high-frequency stimulation in the region of the caudal internal capsule,” Arch. Neurol. 65(2): 264–6.CrossRefGoogle ScholarPubMed
Lowe, T. L., Cohen, D. J., Detlor, J., Kremenitzer, M. W., and Shaywitz, B. A. (1982). “Stimulant medications precipitate Tourette’s syndrome,” JAMA 247(12): 1729–31.CrossRefGoogle ScholarPubMed
Luque, F. A., Selhorst, J. B., and Petruska, P. (1987). “Parkinsonism induced by high-dose cytosine arabinoside,” Mov. Disord. 2(3): 219–22.CrossRefGoogle ScholarPubMed
Mann, S. C., Caroff, S. N., Bleier, H. R., Antelo, R. E., and Un, H. (1990). “Electroconvulsive therapy of the lethal catatonia syndrome,” Convulsive Ther. 6(3): 239–47.Google ScholarPubMed
Marion, M. H., Klap, P., Cohen, M., and Perrin, A. (1992). “Stridor and focal laryngeal dystonia,” Lancet Neurol. 339(8791): 457–8.CrossRefGoogle ScholarPubMed
Mariotti, P., Fasano, A., Contarino, M. F., Della Marca, G., Piastra, M., Genovese, O., et al. (2007). “Management of status dystonicus: our experience and review of the literature,” Mov. Disord. 22(7): 963–8.CrossRefGoogle ScholarPubMed
Martinovits, G. L. G., Goldhammer, Y., and Sadeh, M. (1988). “Vocal cord paralysis as a presenting sign in the Shy-Drager syndrome,” J. Laryngol. Otol. 102(03): 280–1.CrossRefGoogle ScholarPubMed
Matsuda, S., Waragai, M., Shinotoh, H., Takahashi, N., Takagi, K., and Hattori, T. (1999). “Intracranial dural arteriovenous fistula (DAVF) presenting progressive dementia and parkinsonism,” J. Neurol. Sci. 165(1): 43–7.CrossRefGoogle ScholarPubMed
Mehanna, R. and Jankovic, J. (2010). “Respiratory problems in neurologic movement disorders,” Parkinsonism Relat. Disord. 16(10): 628–38.CrossRefGoogle ScholarPubMed
Mehanna, R. and Jankovic, J. (2012). “Respiratory disorders associated with dystonia,” Mov. Disord. 27(14): 1816–19.CrossRefGoogle ScholarPubMed
Mills, K. C. (1997). “Serotonin syndrome. A clinical update,” Crit. Care Clin. 13(4): 763–83.CrossRefGoogle ScholarPubMed
Misra, U. K. and Kalita, J. (2010). “Spectrum of movement disorders in encephalitis,” J. Neurol. 257(12): 2052–8.CrossRefGoogle ScholarPubMed
Miyagi, S., Sekiguchi, S., Kawagishi, N., Akamatsu, Y., Sato, A., Fujimori, K., et al. (2008). “Parkinsonism during cyclosporine treatment in liver transplantation: an unusual case report,” Transpl. P. 40(8): 2823–4.CrossRefGoogle Scholar
Morishita, T., Foote, K. D., Burdick, A. P., Katayama, Y., Yamamoto, T., Frucht, S. J., et al. (2010). “Identification and management of deep brain stimulation intra- and postoperative urgencies and emergencies,” Parkinsonism Rel. Disord. 16(3): 153–62.CrossRefGoogle ScholarPubMed
Murgod, U. A., Muthane, U. B., Ravi, V., Radhesh, S., and Desai, A. (2001). “Persistent movement disorders following Japanese encephalitis,” Neurology 57(12): 2313–15.CrossRefGoogle ScholarPubMed
Netravathi, M., Pal, P. K., Bharath, R. D., and Ravishankar, S. (2011). “Intracranial dural arteriovenous fistula presenting as parkinsonism and cognitive dysfunction,” J. Clin. Neurosci. 18(1): 138–40.CrossRefGoogle ScholarPubMed
Nicholson, A. N. and Turner, E. A. (1964). “Parkinsonism produced by parasagittal meningiomas,” J. Neurosurg. 21: 104–13.CrossRefGoogle ScholarPubMed
Noel, S., Guillaume, M. P., Telerman-Toppet, N., and Cogan, E. (1992). “Movement disorders due to cerebral Toxoplasma gondii infection in patients with the acquired immunodeficiency syndrome (AIDS),” Acta Neurol. Belg. 92(3): 148–56.Google Scholar
Nomoto, K., Scurlock, C., and Bronster, D. (2011). “Dexmedetomidine controls twitch-convulsive syndrome in the course of uremic encephalopathy,” J. Clin. Anesth. 23(8): 646–8.CrossRefGoogle ScholarPubMed
Okun, M. S., Raju, D. V., Walter, B. L., Juncos, J. L., DeLong, M. R., Heilman, K., et al. (2004). “Pseudobulbar crying induced by stimulation in the region of the subthalamic nucleus,” J. Neurol. Neurosurg. Psychiatry. 75(6): 921–3.CrossRefGoogle Scholar
Okun, M. S., Rodriguez, R. L., Foote, K. D., Sudhyadhom, A., Bova, F., Jacobson, C., et al. (2008). “A case-based review of troubleshooting deep brain stimulator issues in movement and neuropsychiatric disorders,” Parkinsonism Rel. Disord. 14(7): 532–8.CrossRefGoogle ScholarPubMed
Olanow, C. W. (2004). “Manganese-induced parkinsonism and Parkinson’s disease,” Ann. NY Acad. Sci. 1012: 209–23.CrossRefGoogle ScholarPubMed
Onofrj, M., Bonanni, L., Cossu, G., Manca, D., Stocchi, F., and Thomas, A. (2009). “Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-dopa gel treatment,” Parkinsonism Rel Disord. 15:(Suppl. 3): S233–6.CrossRefGoogle ScholarPubMed
Onofrj, M. and Thomas, A. (2005). “Acute akinesia in Parkinson disease,” Neurology 64(7): 1162–9.CrossRefGoogle ScholarPubMed
Opal, P., Tintner, R., Jankovic, J., Leung, J., Breakefield, X. O., Friedman, J., et al. (2002). “Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm,” Mov. Disord. 17(2): 339–45.CrossRefGoogle ScholarPubMed
Panzer, J. and Dalmau, J. (2011). “Movement disorders in paraneoplastic and autoimmune disease,” Curr. Opin. Neurol. 24(4): 346–53.CrossRefGoogle ScholarPubMed
Perlmutter, S. J., Leitman, S. F., Garvey, M. A., Hamburger, S., Feldman, E., Leonard, H. L., et al. (1999). “Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood,” Lancet Neurol. 354(9185): 1153–8.CrossRefGoogle ScholarPubMed
Pramstaller, P. P., Salerno, A., Bhatia, K. P., Prugger, M., and Marsden, C. D. (1999). “Primary central nervous system lymphoma presenting with a parkinsonian syndrome of pure akinesia,” J. Neurol. 246(10): 934–8.CrossRefGoogle ScholarPubMed
Quinn, N. (1995). “Parkinsonism – recognition and differential diagnosis,” BMJ 310(6977): 447–52.CrossRefGoogle ScholarPubMed
Rachinger, J., Fellner, F. A., Stieglbauer, K., and Trenkler, J. (2002). “MR changes after acute cyanide intoxication,” Am. J. Neuroradiol. 23(8): 1398–401.Google ScholarPubMed
Radomski, J. W., Dursun, S. M., Reveley, M. A., and Kutcher, S. P. (2000). “An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria,” Med. Hypotheses 55(3): 218–24.CrossRefGoogle ScholarPubMed
Reddy, N. J., Lewis, L. D., Gardner, T. B., Osterling, W., Eskey, C. J., and Nierenberg, D. W. (2007). “Two cases of rapid onset Parkinson’s syndrome following toxic ingestion of ethylene glycol and methanol,” Clin. Pharmacol. Ther. 81(1): 114–21.CrossRefGoogle ScholarPubMed
Reeves, A. L., So, E. L., Sharbrough, F. W., and Krahn, L. E. (1996). “Movement disorders associated with the use of gabapentin,” Epilepsia 37(10): 988–90.CrossRefGoogle ScholarPubMed
De Vera Reyes, J. A. (1970). “Parkinsonian-like syndrome caused by posterior fossa tumor,” J. Neurosurg. 33(5): 599–601.CrossRefGoogle ScholarPubMed
Robottom, B. J., Factor, S. A., and Weiner, W. J. (2011). “Movement disorders emergencies Part 2: hyperkinetic disorders,” Arch. Neurol. 68(6): 719–24.Google ScholarPubMed
Rosenberg, M. R. and Green, M. (1989). “Neuroleptic malignant syndrome: review of response to therapy,” Arch. Intern. Med. 149(9): 1927–31.CrossRefGoogle ScholarPubMed
Sachdev, P. (1993). “Tardive and chronically recurrent oculogyric crises,” Mov. Disord. 8(1): 93–7.CrossRefGoogle ScholarPubMed
Sacks, O. W. and Kohl, M. (1970). “L-dopa and oculogyric crises,” Lancet Neurol. 2(7665): 215–16.CrossRefGoogle ScholarPubMed
Salloway, S., Stewart, C. F., Israeli, L., Morales, X., Rasmussen, S., Blitzer, A., et al. (1996). “Botulinum toxin for refractory vocal tics,” Mov. Disord. 11(6): 746–8.CrossRefGoogle ScholarPubMed
Sandyk, R. (1982). “Parkinsonism caused by chronic subdural haematoma. A case report,” S. Afr. Med. J. 61(16): 595–6.Google ScholarPubMed
Sandyk, R. and Gillman, M. A. (1985). “Lithium-induced visual hallucinations: evidence for possible opioid mediation,” Ann. Neurol. 17(6): 619–20.CrossRefGoogle ScholarPubMed
Sato, Y., Asoh, T., Metoki, N., and Satoh, K. (2003). “Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson’s disease,” J. Neurol. Neurosurg. Psychiatry 74(5): 574–6.CrossRefGoogle ScholarPubMed
Schwarz, N. (1998). “The fate of missed atlanto-axial rotatory subluxation in children,” Arch. Orthop. Trauma Surg. 117(4): 288–9.CrossRefGoogle ScholarPubMed
Scott, B. L., Jankovic, J., and Donovan, D. T. (1996). “Botulinum toxin injection into vocal cord in the treatment of malignant coprolalia associated with Tourette’s syndrome,” Mov. Disord. 11(4): 431–3.CrossRefGoogle ScholarPubMed
Silber, M. H. and Levine, S. (2000). “Stridor and death in multiple system atrophy,” Mov. Disord. 15(4): 699–704.3.0.CO;2-L>CrossRefGoogle ScholarPubMed
Sillay, K. A., Larson, P. S., and Starr, P. A. (2008). “Deep brain stimulator hardware-related infections: incidence and management in a large series,” Neurosurg. 62(2): 360–6; discussion 366–7.CrossRefGoogle Scholar
Snider, L. A. and Swedo, S. E. (2003). “Post-streptococcal autoimmune disorders of the central nervous system,” Curr. Opin. Neurol. 16(3): 359–65.CrossRefGoogle ScholarPubMed
Strawn, J. R.Keck, P. E., and Caroff, S. N. (2007). “Neuroleptic malignant syndrome,” Am. J. Psychiatry 164(6): 870–6.CrossRefGoogle ScholarPubMed
Stubner, S., Rustenbeck, E., Grohmann, R., Wagner, G., Engel, R., Neundorfer, G., et al. (2004). “Severe and uncommon involuntary movement disorders due to psychotropic drugs,” Pharmacopsychiatry 37:(Suppl. 1): S54–64.Google ScholarPubMed
Su, C.-S., Chang, Y.-Y., Liu, K.-T., Lan, M.-Y., and Liu, J.-S. (2012). “Risk factors for prolonged hemichorea-hemiballism caused by hyperglycemia,” Parkinsonism Rel. Disord. 18: 96–8.CrossRefGoogle ScholarPubMed
Subach, B. R., McLaughlin, M. R., Albright, A. L., and Pollack, I. F. (1998). “Current management of pediatric atlantoaxial rotatory subluxation,” Spine 23(20): 2174–9.CrossRefGoogle ScholarPubMed
Susatia, F. and Fernandez, H. H. (2009). “Drug-induced parkinsonism,” Curr. Treat. Options Neurol. 11(3): 162–9.CrossRefGoogle ScholarPubMed
Thanvi, B., Lo, N., and Robinson, T. (2007). “Levodopa-induced dyskinesia in Parkinson’s disease: clinical features, pathogenesis, prevention and treatment,” Postgrad. Med. J. 83(980): 384–8.CrossRefGoogle Scholar
Trollor, J. N. and Sachdev, P. S. (1999). “Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases,” Aust. NZ J. Psychiat. 33(5): 650–9.CrossRefGoogle ScholarPubMed
Vaamonde, J., Narbona, J., Weiser, R., Garcia, M. A., Brannan, T., and Obeso, J. A. (1994). “Dystonic storms: a practical management problem,” Clin. Neuropharmacol. 17: 344–7.CrossRefGoogle ScholarPubMed
Veerapandiyan, A., Gallentine, W. B., Winchester, S. A., Baker, J., Kansagra, S. M., and Mikati, M. A. (2011). “Oculogyric crises secondary to lamotrigine overdosage,” Epilepsia 52(3): e4–6.CrossRefGoogle ScholarPubMed
Visudhiphan, P., Chiemchanya, S., Somburanasin, R., and Dheandhanoo, D. (1982). “Torticollis as the presenting sign in cervical spine infection and tumor,” Clin. Pediatr. 21(2): 71–6.CrossRefGoogle ScholarPubMed
Voon, V., Krack, P., Lang, A. E., Lozano, A. M., Dujardin, K., Schüpbach, M., et al. (2008). “A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s disease,” Brain 131: 2720–8.CrossRefGoogle ScholarPubMed
Wasserstein, P. H. and Honig, L. S. (1996). “Parkinsonism during cyclosporine treatment,” Bone Marrow Transpl. 18(3): 649–50.Google ScholarPubMed
Woodbury, M. M. and Woodbury, M. A. (1992). “Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome,” J. Am. Acad. Child and Adolesc. Psychiatry 31: 1161–4.CrossRefGoogle ScholarPubMed
Wu, Y. R., Chen, C. M., Ro, L. S., Chen, S. T., and Tang, L. M. (1996). “Vocal cord paralysis as an initial sign of multiple system atrophy in the central nervous system,” J. Formos. Med. Assoc. 95(10): 804–6.Google ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Movement disorders emergencies
    • By Ritesh A. Ramdhani, Movement Disorders Division, Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA, Steven J. Frucht, Movement Disorders Division, Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
  • Edited by Werner Poewe, Joseph Jankovic, Baylor College of Medicine, Texas
  • Book: Movement Disorders in Neurologic and Systemic Disease
  • Online publication: 05 April 2014
  • Chapter DOI: https://doi.org/10.1017/CBO9781139175845.028
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Movement disorders emergencies
    • By Ritesh A. Ramdhani, Movement Disorders Division, Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA, Steven J. Frucht, Movement Disorders Division, Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
  • Edited by Werner Poewe, Joseph Jankovic, Baylor College of Medicine, Texas
  • Book: Movement Disorders in Neurologic and Systemic Disease
  • Online publication: 05 April 2014
  • Chapter DOI: https://doi.org/10.1017/CBO9781139175845.028
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Movement disorders emergencies
    • By Ritesh A. Ramdhani, Movement Disorders Division, Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA, Steven J. Frucht, Movement Disorders Division, Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
  • Edited by Werner Poewe, Joseph Jankovic, Baylor College of Medicine, Texas
  • Book: Movement Disorders in Neurologic and Systemic Disease
  • Online publication: 05 April 2014
  • Chapter DOI: https://doi.org/10.1017/CBO9781139175845.028
Available formats
×